Tristel receives three product approvals in the US, Canada, and South Korea

Follow us on Google News:
 Tristel receives three product approvals in the US, Canada, and South Korea
Image source: Microgen,


  • Tristel received three regulatory approvals for its different categories of product.
  • In the US, the company got approval for surface disinfectant from Environmental Protection Agency.
  • The regulatory approvals will allow the company to sell its products and would contribute significantly to revenue growth.

Infection prevention and contamination control products maker, Tristel Plc (LON: TSTL) has bagged three significant approvals for its different categories of products in international markets.

The company is in research and development of disinfectant products for medical instruments cleaning, surface cleaning of hospitals, pharma companies, laboratory and preventive infection products for animal healthcare.

Approval by the US Environmental Protection Agency (EPA)

In the US, the company got approval for surface disinfectant from Environmental Protection Agency (EPA). The submission for product approval was made in October 2020 after completing three state registration of the product. It is a third approval for the form-based Jet product that led to the product’s efficacy claims to include mycobacteria.

The company expects to complete nationwide registration of products by June 2022 and has appointed Parker Laboratories as a manufacturing partner for Jet product. In the US market, the company plans to sell the products from FY23 by using parkers’ existing nationwide network of distribution on a non-exclusive license basis. Before the US product launch in FY23, the company is looking to add other distribution channels as well.

Approval by Health Canada for the disinfectant to clean ophthalmic instruments


Tristel Duo OPH received approval as a class 2 medical device from Health Canada, a department working under the Government of Canada and responsible for national health policy. The product is included in Canada’s Medical Device License listing. Duo OPH is a disinfectant used to clean different types of ophthalmic instruments like ultrasound devices and lenses that are used to examine the outer layer of the eyes.

According to the company, Duo OPH is the best high-level disinfectant used for different ophthalmic devices sold in over 15 countries, with the expected FY21 sales revenue to be £650,000.

For product sales in the Canadian market, the company is currently having a discussion with a potential distribution partner. US-based Parker Laboratories will manufacture Duo OPH product for the Canadian market.

Approval by the South Korea Ministry of Food and Drug Safety

The company received approval from the Korean Ministry of Food and Drug Safety for Sporicidal Wipe. The wipes are widely used in clinics to clean small endoscopic devices used to examine ear, nose and throat.

Duo ULT a hand-held dispenser has been approved as a proficient cleanser for ultrasound devices which uses the company’s powerful chlorine dioxide solution as a foam to the exterior of a medical device. It is widely used across Europe, the Middle East. In South Korea, Tristel’s plans to sell products through its existing distributor HP&C Ltd. The company expects both Duo ULT and Duo OPH combined sales to exceed £4.3 million in FY21.


Tristel’s reported total revenue stood at £31.68 million in 2020 with pretax profits of £6.64 million and a dividend 5.84p per share. The stock has a dividend yield of 1.06%.

After the announcement, Tristel’s stock was trading at GBX 625 at 11:23 AM GMT+1 with a market cap of £ 294 million. In the last 1-year, the stock has given 44% returns to its shareholders.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Featured Articles